Case Presentation
A 12-year-old male presented to the neuro-ophthalmology clinic with a complaint of reduced vision in the left eye and a history of visual difficulties since early childhood.
The patient’s parents reported that he had been misdiagnosed with amblyopia despite compliance with optical correction and patching therapy, with minimal improvement in visual function.
Physical examination revealed bilateral small optic discs with asymmetric cup-to-disc ratios, circumferential hypopigmentary changes, and bilateral optic nerve hypoplasia.
Optical coherence tomography of the macula demonstrated a flattened foveal umbo in the left eye with a lack of diminution of inner retinal layers.
Perimetry revealed bitemporal visual field defects. Magnetic resonance imaging showed marked symmetrical optic nerve atrophy in both eyes and an absent septum pellucidum without a compressive lesion.
The pituitary gland appeared radiologically normal. A diagnosis of Septo-optic Dysplasia was made.
Disease Overview
Septo-optic dysplasia, also known as de Morsier syndrome, is a rare congenital disorder characterized by midline brain malformations.
This condition represents a spectrum of abnormalities involving the optic nerves, hypothalamic-pituitary axis, and midline cerebral structures.
The disorder is clinically important for ophthalmologists because optic nerve hypoplasia is frequently the presenting sign, and comprehensive ocular evaluation may lead to early diagnosis and appropriate systemic management.
The syndrome demonstrates variable phenotypic penetration, resulting in highly heterogeneous clinical presentations.
Some patients present with severe visual impairment and multiple systemic complications, while others maintain relatively preserved vision with isolated midline defects.
Early recognition of septo-optic dysplasia enables timely referral for endocrine evaluation and neurological assessment, which can significantly impact long-term patient outcomes.
Pathophysiolog
Septo-optic dysplasia arises from abnormal development of midline neural structures during embryogenesis. The optic nerve develops from the diencephalon and optic cup during weeks 5-7 of gestation.
Disruption of these developmental processes results in optic nerve hypoplasia, characterized by underdevelopment of the optic nerve with reduced numbers of axons and supporting glial tissue.
The septum pellucidum and corpus callosum develop from the commissural plate during the first trimester. Failure of midline development results in agenesis or hypoplasia of these structures.
The hypothalamic-pituitary axis develops from two distinct sources—the infundibulum from the ventral diencephalon and Rathke’s pouch from the adenohypophyseal primordium.
Abnormal development results in variable degrees of pituitary gland hypoplasia and hormonal insufficiency.
The clinical heterogeneity observed in septo-optic dysplasia is attributed to variable genetic mutations and environmental factors affecting the timing and extent of midline development.
Multiple genes have been implicated, including HESX1, SOX2, OTX2, and TUBA1A. The TUBB gene mutation has been identified in association with facial dysmorphism and septo-optic dysplasia.
The severity and pattern of neural underdevelopment determine the spectrum of clinical manifestations observed in individual patients.
Epidemiology
Septo-optic dysplasia is a rare congenital disorder with an estimated incidence ranging from 1 in 10,000 to 1 in 50,000 live births.
The condition typically presents during infancy or early childhood, with nystagmus often appreciated by three months of age in cases of bilateral optic nerve involvement.
There is no significant gender predominance reported in the literature.
Risk factors include genetic predisposition from identified mutations in developmental genes and potential environmental factors, though specific environmental triggers remain incompletely characterized.
The condition may occur sporadically or as part of familial genetic syndromes. Prenatal factors and perinatal complications have been investigated, but definitive causal associations have not been established.
The variable clinical presentation means that milder cases may not be diagnosed until later childhood or even adulthood, when visual impairment becomes apparent during routine examination.
Clinical Features
- Nystagmus, typically the chief finding in newborns with bilateral optic nerve hypoplasia, is usually apparent by three months of age
- Strabismus, frequently occurring in the first year of life, is associated with both bilateral and unilateral optic nerve involvement
- Reduced visual acuity ranging from no light perception to relatively normal vision, with approximately 23% of patients experiencing no light perception
- Esotropia and enophthalmos
- Astigmatism, myopia, or hyperopia with potential reduction in contrast sensitivity
- Amblyopia secondary to optic nerve underdevelopment or strabismus
- Visual field defects, including bitemporal hemianopia, generalized constriction, central scotoma, or altitudinal defects
- Seizures occurring in some patients with significant midline malformations
- Developmental delay and cognitive impairment, varying in severity
- Cerebral palsy is present in a subset of affected individuals
- Growth abnormalities related to growth hormone deficiency
- Delayed growth and developmental milestones in cases with hypothalamic-pituitary dysfunction, Progressive
- loss of visual acuity during infancy or adulthood, with 80% of bilateral cases becoming legally blind at some point
- Endocrine manifestations, including growth hormone deficiency, secondary hypothyroidism, adrenal insufficiency, or gonadotropin deficiency
Examination Findings
- Visual acuity: variable presentation from light perception only to relatively normal acuity; asymmetric involvement is common
- Pupillary responses: pupils may be equal and reactive to light, though responses may be absent or severely sluggish
- Optic nerve appearance: bilateral or unilateral optic nerve hypoplasia with small optic disc diameter, reduced neuroretinal rim, and variable cup-to-disc ratios
- Optic disc color: may demonstrate pallor or atrophic appearance with circumferential hypopigmentary changes
- Optic nerve hypoplasia: may present with “double ring” sign on imaging, representing the border between hypoplastic and normal retina
- Retinal vasculature: often enlarged with reduced vascular caliber relative to disc size
- Motility disturbances: nystagmus, strabismus, abnormal saccadic movements, and impaired fixation
- Fundus examination: flat and dry macula with notably absent foveal light reflex, particularly in severely affected eyes
- Optical coherence tomography findings: extensive diffuse retinal nerve fiber layer thinning bilaterally; flattened foveal umbo; continued inner retinal layers at foveal pit; small overall disc size
- Macular OCT: normal macular architecture may be preserved in less severely affected eyes
- Visual field testing: bitemporal hemianopia, generalized constricted fields, central scotoma, binasal scotoma, or altitudinal defects
- Electroretinography: assessment of retinal function with evaluation of amplitude, latency, and photic responses
- Visual evoked potential: typically demonstrates delayed latency along optic nerves, reflecting optic nerve conduction abnormalities
- Magnetic resonance imaging: marked optic nerve atrophy, absent or hypoplastic septum pellucidum, absent or hypoplastic corpus callosum, normal or hypoplastic pituitary gland without compressive lesion
Differential Diagnosis
- Optic nerve hypoplasia from other causes, including isolated optic nerve underdevelopment without midline involvement
- Amblyopia from refractive error or strabismus, which may coexist but should not delay recognition of underlying structural pathology
- Optic nerve atrophy from acquired causes, including history of raised intracranial pressure or demyelinating disease
- Optic nerve coloboma, which may present with similar visual field defects but lacks midline brain involvement
- Morning glory disc anomaly, characterized by optic nerve enlargement rather than hypoplasia
- Congenital cataracts or anterior segment malformations causing visual impairment
- Leber congenital amaurosis, presenting with severe visual impairment and nystagmus in infants
- Cortical visual impairment from primary brain malformation without optic nerve involvement
- Pituitary adenoma or other sellar mass causing compression of the optic pathways
Diagnosis
Diagnosis of septo-optic dysplasia requires identification of at least two components of the classical clinical triad: optic nerve hypoplasia, agenesis or hypoplasia of the septum pellucidum, and hypothalamic-pituitary axis dysfunction.
A comprehensive ophthalmologic examination is essential for the recognition of optic nerve hypoplasia and associated ocular manifestations.
Magnetic resonance imaging of the brain is the gold standard imaging modality for confirming septo-optic dysplasia.
High-resolution MRI with dedicated protocols for the optic pathway and pituitary gland demonstrates optic nerve atrophy, midline brain defects, and pituitary abnormalities.
MRI should be obtained in any patient with unexplained optic nerve hypoplasia or optic atrophy to exclude compressive lesions and confirm the diagnosis.
Optical coherence tomography plays an important adjunctive diagnostic role, enabling measurement of retinal nerve fiber layer thickness and assessment of macular architecture.
OCT findings of diffuse RNFL thinning and the “double ring” sign support the diagnosis. Visual field testing reveals characteristic defects such as bitemporal hemianopia related to involvement of the optic chiasm.
Electroretinography and visual evoked potential testing provide an objective assessment of retinal and optic nerve function.
VEP typically demonstrates prolonged latency consistent with optic nerve conduction impairment.
Endocrinologic evaluation, including assessment of growth hormone, thyroid function, adrenocorticotropic hormone, and gonadotropin levels, is essential to identify hormonal deficiencies requiring replacement therapy.
Management
Ophthalmologic Management
Comprehensive ophthalmologic care forms the foundation of septo-optic dysplasia management.
Accurate refraction and optical correction of refractive errors are essential, as these contribute to visual dysfunction independent of structural pathology.
Appropriate spectacle prescription may improve visual acuity and should be implemented early in childhood to facilitate normal visual development and educational achievement.
Assessment for amblyopia is critical, as refractive error or strabismus may contribute to functional vision loss superimposed on structural optic nerve hypoplasia.
Occlusion therapy may be considered in selected cases with significant interocular visual acuity differences, though response rates are often limited by the underlying structural pathology.
Protective eyewear is recommended to reduce the risk of trauma in patients with reduced vision or visual field defects.
Strabismus correction through surgical intervention may be considered when significant misalignment impairs fusion or cosmetic appearance.
Surgery should be deferred until adequate visual assessment has been completed and realistic goals established.
Periodic ophthalmologic follow-up is necessary to monitor for progressive visual decline and to ensure appropriate management of refractive and motility disturbances.
Endocrinologic Management
Early identification and treatment of hypothalamic-pituitary axis dysfunction is essential to optimize growth and development.
Growth hormone replacement therapy should be initiated in patients with documented growth hormone deficiency, as early treatment improves final adult height and metabolic outcomes.
Thyroid hormone replacement is indicated for secondary hypothyroidism, and adrenal hormone replacement is necessary for adrenal insufficiency.
Gonadotropin replacement may be required at puberty in patients with hypogonadotropic hypogonadism.
Hormone levels should be monitored regularly, with dose adjustments made to maintain physiologic levels. Close collaboration between ophthalmology and endocrinology is essential to coordinate comprehensive management.
Neurologic Management
Seizure management with appropriate anticonvulsant therapy is indicated in patients presenting with seizures.
Neurologic assessment should evaluate for developmental delay and cerebral palsy, with early intervention programs implemented when developmental abnormalities are identified.
Neuroimaging should be reviewed for associated cortical malformations requiring specific management.
Observation and Follow-up
The non-progressive nature of septo-optic dysplasia distinguishes it from other optic neuropathies, though functional visual decline may occur from secondary factors.
However, 80% of patients with bilateral optic nerve hypoplasia eventually develop legal blindness.
Regular ophthalmologic follow-up is recommended to assess visual function, monitor for progressive vision loss, and identify secondary complications requiring intervention.
Prognosis
Visual prognosis in septo-optic dysplasia is highly variable and depends on several factors. Patients with unilateral optic nerve hypoplasia may preserve normal visual acuity bilaterally, representing a favorable prognostic subset.
Bilateral optic nerve involvement carries a more guarded prognosis, with 80% of patients eventually developing legal blindness.
Initial visual acuity is a significant predictor of long-term visual outcome. Optic disc size and visual evoked potential latency also provide prognostic information.
The presence and extent of retinal nerve fiber layer thinning on OCT correlate with final visual acuity.
Interestingly, continuation of inner retinal layers at the foveal pit, observable on macular OCT, has been associated with better visual outcomes in some studies.
Endocrinologic complications significantly impact overall prognosis, making early recognition and treatment of growth hormone deficiency and other hormonal abnormalities essential.
Neurologic complications, including seizures and developmental delay, influence long-term developmental trajectories.
Long-term management requires multidisciplinary coordination among ophthalmology, endocrinology, neurology, and developmental pediatrics to optimize visual function, growth, neurologic development, and overall quality of life.
Prevention
Primary prevention of septo-optic dysplasia is not currently possible, as the condition results from intrinsic genetic mutations and developmental anomalies occurring during embryogenesis.
Genetic counseling is appropriate for families with identified heritable forms of septo-optic dysplasia, though most cases occur sporadically.
Early identification through routine newborn and infant eye screening is crucial, as detection of nystagmus or optic nerve abnormalities in early infancy enables prompt diagnostic evaluation and treatment initiation.
Screening programs should include assessment for optic nerve hypoplasia in any infant presenting with nystagmus or visual impairment.
Secondary prevention focuses on early diagnosis, appropriate referral for systemic evaluation, and timely initiation of hormone replacement therapy to minimize complications.
diagnosis, comprehensive ocular assessment, and long-term visual surveillance.
Would you have interest in taking retinal images with your smartphone?
Fundus photography is superior to fundus analysis as it enables intraocular pathologies to be photo-captured and encrypted information to be shared with colleagues and patients.
Recent technologies allow smartphone-based attachments and integrated lens adaptors to transform the smartphone into a portable fundus camera and Retinal imaging by smartphone.
RETINAL IMAGING BY YOUR SMARTPHONE
References
[1] Al-Salihi MM. The clinical aspects of septo-optic dysplasia. PubMed Central. 2023.
[2] Cappelli OD. Ocular manifestations of septo-optic dysplasia. The Athenaeum. 2023.
[3] Campbell CL. Septo-optic dysplasia: a literature review. PubMed. 2003.
[4] Ganau M. Neuro-ophthalmological manifestations of septo-optic dysplasia: current perspectives. Dove Press. 2019.
[5] Nalawade R. Septo-optic dysplasia: a case series of 33 patients. Taylor & Francis Online. 2024.
